Table 1. Response to anti-VEGF therapy in n-AMD.

Response	Morphology	Functional
Good	Absence of SRF, IRF, IRC or a reduction of CRT >75% of the baseline values	Improvement in VA >5 letters from the baseline (ceiling effect in eyes with good starting VA defined as ETDRS 70 letters or above). Pay more attention to morphological features if VA is good esp >70)
Partial	Reduction of CRT of between 25 and 75% of the baseline values, and/or persistence of SRF, IRF, IRC and or appearance of new IRC, IRF and SRF	Change in VA of 1–5 letters from the baseline
Poor	Between 0 and <25% reduction in CRT and/or persistence of SRF, IRF, IRC and or appearance of new IRC, IRF and SRF	Change in VA of 0−4 letters
Non-response	Unchanging or increasing CRT, SRF, IRF and/or PED compared with the baseline	Change >−5 letters ie decline in VA from the baseline from 1 month after third initiation injection

Abbreviations: CRT, central retinal thickness in the central 1000-μm subfield; IRC, intraretinal cysts; IRF, intraretinal fluid; SRF, subretinal fluid.

Notes: 1. Retinal atrophy/thinning and/or subretinal fibrosis do not imply poor response, but confound VA.Similarly, minimal change of fluid over scar tissue etc may not imply poor response. These may resultfrom longstanding disease, rather than treatment outcomes.

2. Outer retinal tubulations (ORT) do not represent active fluid leakage.

3. PED presence - evidence to date does not indicate that flattening of PED determines outcomes;however, PED progression indicates active disease and requires ICGA to exclude IPCV, and/orconsideration of treatment change.

4. Morphological and functional features (responses) may not correlate.

5. Primary response determined after initiation phase ie at first visit after the 3rd initiation injection.

6. Secondary response determined any time from 1 month after the 3rd initiation injection (months 4–11).

7. Late response determined at month 12 or after.